
Cigna Healthcare is owned by The Cigna Group (NYSE: CI), a publicly traded healthcare company headquartered in Bloomfield, Connecticut. The Cigna Group operates Cigna Healthcare as its primary health insurance division, serving approximately 18.1 million medical customers as of 2025. The parent company reported $247.1 billion in total revenues for 2024. In March 2025, The Cigna Group completed the sale of its Medicare Advantage business to Health Care Service Corporation for approximately $3.3 billion.
Parent Company
Founded
1982
Status
Publicly Traded
Headquarters
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Cigna Healthcare | The Cigna Group | Brand division |
Cigna Healthcare traces its origins to 1982, when the Connecticut General Life Insurance Company (CG, founded 1865) and the Insurance Company of North America (INA, founded 1792) merged to form Cigna Corporation. The merger created one of the largest insurance organizations in the United States, combining CG's life and health insurance operations with INA's property and casualty business. The name "Cigna" combined elements of both predecessor companies: "CG" and "INA."
Throughout the 1980s, Cigna expanded its health insurance operations through acquisitions and organic growth. The company acquired Equicor in 1989, adding managed care capabilities. During this period, Cigna built its health maintenance organization (HMO) network and began offering preferred provider organization (PPO) plans, responding to the rise of managed care in the American healthcare system.
In the 1990s, Cigna continued to grow its health benefits business. The company acquired Healthsource in 1997 for $1.7 billion, expanding its HMO membership to approximately 5 million. This acquisition strengthened Cigna's position in the employer-sponsored insurance market. By the end of the decade, Cigna had divested its property and casualty insurance operations to focus on health benefits and related services.
The 2000s brought further strategic shifts. In 2004, Cigna acquired Great West Healthcare for $1.2 billion, adding regional health plan membership in Colorado and other western states. The company also began investing in consumer-directed health plans, including health savings account (HSA) compatible products, as employers shifted toward high-deductible health plans.
In 2011, David Cordani became CEO of Cigna. Under his leadership, the company pursued international expansion and diversified its healthcare offerings. Cigna acquired HealthSpring in 2012 for $3.8 billion, entering the Medicare Advantage market. The company also expanded its international health benefits business, serving multinational employers and globally mobile individuals.
The most significant transformation came in 2018, when Cigna acquired Express Scripts, the largest pharmacy benefit manager in the United States, for approximately $52 billion. The deal closed in December 2018 and created a combined company with revenues exceeding $100 billion. Following the acquisition, Cigna reorganized into two primary segments: Evernorth Health Services (pharmacy benefits) and Cigna Healthcare (health insurance). In 2023, the company rebranded its corporate name from Cigna Corporation to The Cigna Group to reflect this diversified structure.
In January 2024, The Cigna Group announced the sale of its Medicare businesses to HCSC. The transaction closed in March 2025, marking a strategic exit from the government-backed Medicare market. The company stated that the divestiture would streamline its portfolio and allow it to focus on commercial health insurance and pharmacy benefit services. The Cigna Group projected 2025 adjusted revenues of at least $252 billion and adjusted income from operations of at least $7.9 billion.
What does The Cigna Group own?
The Cigna Group owns Cigna Healthcare (health insurance products including medical, dental, behavioral health, and vision plans), Express Scripts (pharmacy benefits management), Evernorth Health Services (specialty pharmacy and care coordination), Cigna Dental, Cigna Pharmacy, and Cigna Global Health Benefits. In 2025, the company sold its Medicare Advantage, Medicare Supplemental Benefits, Medicare Part D, and CareAllies businesses to Health Care Service Corporation.
Is The Cigna Group publicly traded?
Yes, The Cigna Group is publicly traded on the New York Stock Exchange under ticker symbol CI. The company has been publicly traded since its formation in 1982 and is a component of the S&P 500 Index, ranked No. 13 on the Fortune 500.
Who founded The Cigna Group?
The Cigna Group was founded in 1982 through the merger of Connecticut General Life Insurance Company (founded 1865 in Hartford, Connecticut) and Insurance Company of North America (founded 1792 in Philadelphia, one of the oldest insurance companies in America). The company was renamed The Cigna Group in February 2023.
Where is The Cigna Group headquartered?
The Cigna Group is headquartered at 900 Cottage Grove Road, Bloomfield, Connecticut 06002, USA. The company operates in more than 30 markets and jurisdictions worldwide.
How many brands does The Cigna Group own?
The Cigna Group's principal brands are Cigna Healthcare, Express Scripts, and Evernorth Health Services. These umbrella brands cover health insurance, pharmacy benefits management, dental insurance, pharmacy services, and international health benefits.
Who owns The Cigna Group?
The Cigna Group is publicly owned with a dispersed shareholder base. Institutional investors hold the majority of shares, with no single controlling shareholder. Major institutional shareholders include Vanguard Group, BlackRock, and State Street Global Advisors, typical of S&P 500 companies.
What is The Cigna Group's revenue?
For FY2025, The Cigna Group reported total revenues of $274.9 billion, up 11% from $247.1 billion in FY2024. Shareholders' net income was $6.0 billion, or $22.18 per share. Adjusted income from operations was $8.0 billion, or $29.84 per share. For 2026, the company projects adjusted revenues of approximately $280 billion.
Has The Cigna Group made major changes recently?
Yes. In March 2025, Cigna completed the sale of its Medicare Advantage and related businesses to HCSC. In October 2025, Express Scripts announced a new rebate-free PBM model. In February 2026, Express Scripts reached a landmark settlement with the FTC over insulin pricing practices. The company also increased its quarterly dividend to $1.56 per share.
Cigna Healthcare and The Cigna Group have received recognition from several independent organizations. The National Committee for Quality Assurance (NCQA) has accredited multiple Cigna Healthcare commercial health plans, a standard for health plan quality measurement in the United States.
The Cigna Group has been included on the Ethisphere Institute's list of the World's Most Ethical Companies multiple times, most recently in 2025. This recognition evaluates corporate ethics and compliance programs. The company has also appeared on Fortune's World's Most Admired Companies list in the healthcare sector.
For workplace culture, The Cigna Group has received recognition from the Human Rights Campaign Foundation's Corporate Equality Index, scoring 100% in recent years for LGBTQ+ workplace inclusion. The company has also been recognized by Forbes as one of America's Best Employers for Diversity.
Cigna Healthcare's Medicare Advantage plans previously received 4-star ratings from CMS (Centers for Medicare and Medicaid Services), though these plans were sold to HCSC in March 2025. The brand's commercial plans continue to receive NCQA accreditation, which is the primary independent quality benchmark for health insurance products.
Cigna Healthcare has faced several regulatory and legal challenges. In 2023, a class-action lawsuit alleged that Cigna used an automated claims review system called PXDX to deny thousands of claims without individual physician review. The lawsuit, filed in California federal court, claimed the system rejected claims in an average of 1.2 seconds each. Cigna stated that PXDX was used to deny claims that did not meet clinical criteria and that physicians reviewed denial decisions. The case is ongoing as of 2025.
In 2024, Cigna Healthcare faced regulatory scrutiny over mental health and substance use disorder treatment denials. Several states investigated whether the company violated mental health parity laws, which require insurers to cover mental health treatment at the same level as physical health treatment. The company settled with some state regulators and agreed to improve claims processing for behavioral health services.
Data privacy has also been an issue. In 2023, Cigna disclosed a data breach affecting approximately 1.5 million customers, caused by a vulnerability in a third-party vendor's systems. The company offered affected customers free credit monitoring and identity theft protection. Regulatory investigations followed, and the company implemented additional vendor security requirements.
Following the Express Scripts acquisition, Cigna Healthcare has faced criticism regarding pharmacy benefit management practices. The Federal Trade Commission has conducted ongoing investigations into the business practices of major pharmacy benefit managers, including Express Scripts, focusing on drug pricing, formulary design, and pharmacy network arrangements. The FTC published an interim staff report in 2024 criticizing PBM practices. The Cigna Group has stated that its pharmacy benefit services reduce drug costs for clients and members.
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Cvs Health | United States | 1853 | Mass market | North america | All Genders | |
| Unitedhealth Group | USA | 1977 | Mass market | United states | All-ages | |
| Centene | USA | 1985 | Mass market | United states | All-ages | |
| Elevance Health | USA | 2024 | Mass market | United states | All-ages | |
| Cigna | USA | 1982 | Mass market | United states | All Genders | |
| Cigna | USA | 2018 | Mass market | United states | All Genders |
Healthcare PharmaceuticalsOwned by CVS Health Corporation
American managed care and health insurance company offering medical, dental, pharmacy, and behavioral health plans, operating as a subsidiary of CVS Health Corporation.
Healthcare PharmaceuticalsOwned by UnitedHealth Group
UnitedHealth Group's health insurance brand providing coverage for individuals, employers, Medicare, and Medicaid recipients.
Healthcare PharmaceuticalsOwned by Centene Corporation
Centene Corporation's national Medicare Advantage and prescription drug plan brand, acquired from WellCare Health Plans for $17.3 billion in January 2020.
Healthcare PharmaceuticalsOwned by Elevance Health Inc.
Elevance Health's government health plan brand for Medicaid, CHIP, and Medicare in states where Anthem Blue Cross Blue Shield does not operate, rebranded from Amerigroup in January 2024.
Healthcare PharmaceuticalsOwned by The Cigna Group
Dental insurance brand offered by The Cigna Group, providing individual, family, and employer-sponsored dental plans across the United States. Cigna Group reported $71.7 billion in Q2 2026 revenue.
Healthcare PharmaceuticalsOwned by The Cigna Group
American pharmacy services brand providing prescription drug coverage, medication management, and pharmacy benefits through The Cigna Group's Evernorth Health Services division.
Market Positioning: Cigna Healthcare competes with 6 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Looking for brands with different ownership structures? These similar brands are not owned by The Cigna Group, giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsOwned by Chempro Chemists
Australian online pharmacy operated by Chempro Chemists from Molendinar, Queensland. Offers prescription medications, health products, and wellness items through digital platforms and mail-order delivery.
Pharmacy Direct is privately owned, unlike Cigna Healthcare which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by GoodRx Holdings, Inc.
American healthcare technology platform providing prescription drug price comparison, discount coupons, and telehealth services to help consumers find affordable healthcare options.
GoodRx operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by Herbalife Ltd.
Global nutrition and weight-management brand owned by Herbalife Ltd. and sold through independent distributors in more than 90 markets.
Herbalife operates independently without a large parent corporation.
Healthcare PharmaceuticalsOwned by EKR Therapeutics, Inc.
Retavase (reteplase) is a prescription thrombolytic medication indicated for acute ST-elevation myocardial infarction. Administered as two 10-unit intravenous bolus injections 30 minutes apart. Currently marketed by Chiesi USA.
Retavase is privately owned, unlike Cigna Healthcare which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by IBSA Institut Biochimique S.A.
IBSA Institut Biochimique SA's branded levothyroxine softgel capsule (Tirosint) and liquid solution (Tirosint-SOL), FDA approved for hypothyroidism, formulated without dyes, gluten, lactose, alcohol, or sugar, providing an excipient-free alternative to conventional levothyroxine tablets for patients with sensitivities or absorption issues.
Tirosint is privately owned, unlike Cigna Healthcare which is under a publicly traded parent company.
Healthcare PharmaceuticalsOwned by GE HealthCare Technologies Inc.
Independent publicly traded healthcare technology company spun off from General Electric in January 2023, providing medical imaging, diagnostics, and healthcare IT solutions globally.
GE HealthCare operates independently without a large parent corporation.
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.

Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.

Prescription isotretinoin brand developed by Roche and approved by the FDA in 1982 for severe nodular acne. Roche discontinued the brand name in the United States in 2009; the drug continues as Roaccutane in international markets.

Activase (alteplase) is a prescription thrombolytic medication manufactured by Genentech, a wholly-owned subsidiary of Roche. Used to treat acute ischemic stroke, heart attack, and pulmonary embolism.